[A20-120] Sucroferric oxyhydroxide (hyperphosphataemia in children and adolescents 2 years of age and older with CKD stages 4-5 or with CKD on dialysis) - Benefit assessment according to §35a Social Code Book V
Last updated 15.03.2021
Project no.:
A20-120
Commission:
Commission awarded on 14.12.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Children's and adolescents' health
Control of serum phosphorus levels in paediatric patients 2 years of age and older with chronic kidney disease (CKD) stages 4 to 5 (defined by a glomerular filtration rate < 30 mL/min/1.73 m²) or with CKD on dialysis
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A14-37 | Sucroferric oxyhydroxide - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |